Aligos Therapeutics (ALGS) Competitors $18.63 -2.22 (-10.65%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$19.14 +0.52 (+2.76%) As of 02/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALGS vs. TSHA, CYRX, ANNX, CRVS, TRVI, CMPS, AQST, GOSS, CADL, and ATYRShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Taysha Gene Therapies (TSHA), Cryoport (CYRX), Annexon (ANNX), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), COMPASS Pathways (CMPS), Aquestive Therapeutics (AQST), Gossamer Bio (GOSS), Candel Therapeutics (CADL), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Taysha Gene Therapies Cryoport Annexon Corvus Pharmaceuticals Trevi Therapeutics COMPASS Pathways Aquestive Therapeutics Gossamer Bio Candel Therapeutics Atyr PHARMA Taysha Gene Therapies (NASDAQ:TSHA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk. Do analysts prefer TSHA or ALGS? Taysha Gene Therapies currently has a consensus target price of $6.63, indicating a potential upside of 311.49%. Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 302.58%. Given Taysha Gene Therapies' higher possible upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, TSHA or ALGS? Taysha Gene Therapies has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.45, indicating that its share price is 145% more volatile than the S&P 500. Is TSHA or ALGS more profitable? Taysha Gene Therapies has a net margin of -229.67% compared to Aligos Therapeutics' net margin of -1,283.19%. Taysha Gene Therapies' return on equity of -106.36% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Aligos Therapeutics -1,283.19%-114.34%-64.58% Does the media favor TSHA or ALGS? In the previous week, Taysha Gene Therapies had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Taysha Gene Therapies and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.42 beat Taysha Gene Therapies' score of 0.41 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, TSHA or ALGS? Aligos Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$15.45M21.36-$111.57M$0.632.56Aligos Therapeutics$15.53M4.31-$87.68M-$13.32-1.40 Do insiders and institutionals have more ownership in TSHA or ALGS? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by insiders. Comparatively, 8.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer TSHA or ALGS? Taysha Gene Therapies received 78 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 77.21% of users gave Taysha Gene Therapies an outperform vote while only 65.85% of users gave Aligos Therapeutics an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes10577.21% Underperform Votes3122.79% Aligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% SummaryTaysha Gene Therapies beats Aligos Therapeutics on 11 of the 16 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.81M$3.12B$5.85B$9.15BDividend YieldN/A1.56%4.76%3.85%P/E RatioN/A10.3116.5114.19Price / Sales4.31327.11450.0276.60Price / CashN/A168.8538.0134.95Price / Book0.613.687.644.63Net Income-$87.68M-$71.72M$3.18B$245.69M7 Day Performance-21.29%-2.46%-1.95%-2.68%1 Month Performance-43.30%-0.25%-0.23%-2.16%1 Year Performance-6.85%-12.31%16.69%12.90% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.5035 of 5 stars$18.63-10.6%$75.00+302.6%+11.9%$74.81M$15.53M0.0090Positive NewsGap UpTSHATaysha Gene Therapies2.346 of 5 stars$1.63+0.6%$6.63+306.4%-36.1%$334.05M$15.45M2.59180CYRXCryoport2.5882 of 5 stars$6.73+0.4%$12.29+82.6%-61.4%$332.66M$233.26M-1.991,170Positive NewsANNXAnnexon2.556 of 5 stars$3.07+2.0%$15.80+414.7%-42.8%$327.23MN/A-2.9260News CoverageGap UpCRVSCorvus Pharmaceuticals2.6908 of 5 stars$4.88-0.8%$12.38+153.6%+82.2%$313.59MN/A-5.2530News CoverageTRVITrevi Therapeutics2.7542 of 5 stars$4.07+1.5%$9.31+128.8%+73.6%$312.86MN/A-9.2520News CoveragePositive NewsGap UpCMPSCOMPASS Pathways1.7 of 5 stars$4.57+3.4%$30.60+569.6%-57.6%$312.68MN/A-2.08120Gap UpAQSTAquestive Therapeutics2.1552 of 5 stars$3.32-4.3%$11.00+231.3%+19.9%$302.72M$50.58M-7.38160Short Interest ↓Positive NewsGOSSGossamer Bio3.9776 of 5 stars$1.31flat$9.20+602.3%+14.8%$296.85MN/A-4.09180High Trading VolumeCADLCandel Therapeutics3.5647 of 5 stars$9.05+2.6%$17.00+87.8%+560.8%$293.91M$120,000.00-5.2360Analyst ForecastNews CoverageATYRAtyr PHARMA2.8166 of 5 stars$3.41-5.0%$19.25+464.5%N/A$286.24M$350,000.00-3.6353Analyst ForecastAnalyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies Taysha Gene Therapies Competitors Cryoport Competitors Annexon Competitors Corvus Pharmaceuticals Competitors Trevi Therapeutics Competitors COMPASS Pathways Competitors Aquestive Therapeutics Competitors Gossamer Bio Competitors Candel Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALGS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALGS Stock Alerts